Citi reinstated coverage of Novo Nordisk with a Buy rating and DKK 975 price target. The analyst believes the market is underappreciating Novo’s “ambition with respect to scaling GLP-1 supply” as well as the upcoming data from the company’s trials for its blockbuster obesity and diabetes treatments.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk price target raised to DKK 930 from DKK 800 at Morgan Stanley
- Novo Nordisk call volume above normal and directionally bullish
- Novo Nordisk price target raised to DKK 850 from DKK 650 at Berenberg
- Vivani announces NPM-115 preclinical weight loss data vs. Ozempic /Wegovy
- Viking Therapeutics soars after obesity drug trial hits targets